A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
302actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-05 | actual | When the study began enrolling |
| Primary completion | 2026-05-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-14 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis
- Psoriatic Arthritis
Intervention
- Drug: Leflunomide — also filed as ARAVA®
Primary outcomes
what the primary-completion date above is the date OFNumber of healthcare professionals who recall receiving and reading the additional risk minimization measures material for leflunomide distributed in 2022
measured 7 months
Number of healthcare professionals aware of the information reported in the educational materials and additional risk minimization measures material distributed in 2022
measured 7 months
Number of healthcare professionals reported counseling their patients and conducting the needed laboratory investigations according to 2022 additional risk minimization measures material
measured 7 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed